Clinical Network Services launches UK office

Clinical Network Services (CNS), which provides broad services in the planning, implementation and delivery of preclinical, Phase 1 and 2 trials, has opened an office in St Albans, headed by Paul Cronin who joins as UK Director and Director, Business Development. The location was chosen for its proximity to the European Medicines Agency (EMA) and the UK MHRA both of which are based in London. The new venture is primarily a BioDesk initiative which Paul will lead in support of CNS clients requiring access to the European regulatory agencies as well as European clients seeking entry to Australia and New Zealand. CNS will continue to undertake its core business of conducting early phase clinical trials in Australian & New Zealand given the simplicity of regulatory review and time advantages for this region.

The Company has also launched a new Biometrics service led by Otto Damsma, Director of Biometrics and Glynn Morrish as Pharmacometrician/Biostatistician at its Brisbane headquarters.

“I’m really pleased to be joining such a dynamic team and look forward to working closely with the Australian and UK operational teams to develop the CNS business across Europe and more generally the norternhemisphere,” Paul Cronin said.
 

Russell Neal, Managing Director of CNS added: “By opening the UK office and making these three strategic hires; CNS is fast becoming the leading Australian supplier of strategic product development advice and early stage clinical development support to small to medium sized biotechnology companies. Paul is widely regarded in international and local industry circles and Otto and Glynn are both considered experts in their fields, bringing a wealth of knowledge to our team that will deliver an ongoing advantage of our clients at home and abroad.”